SystHERs Registry Study: An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer
Dr. Charles Kuzma
Men or women, ages 18 and older, diagnosed with Stage I, II or III breast cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer. Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.